Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance

Background: Treatment utilization/costs and work performance for persons with major depressive disorder (MDD) by severity of illness is not well documented. Methods: Using National Comorbidity Survey‐Replication (2001–2002) data, US workforce respondents (n=4,465) were classified by clinical severity (not clinically depressed, mild, moderate, severe) using a standard self‐rating scale [Quick Inventory of Depressive Symptomatology Self‐Report (QIDS‐SR)]. Outcomes included 12‐month prevalence of medical services/medications use/costs and workplace performance. Treatment costs (employer's perspective) were estimated by weighing utilization measures by unit costs obtained for similar services used by MDD patients in claims data. Descriptive analysis across three severity groups generated χ2 results. Results: Using a sample of 539 US workforce respondents with MDD, 13.8% were classified mild, 38.5% moderate, and 47.7% severe cases. Mental health services usage, including antidepressants, increased significantly with severity, with average treatment costs substantially higher for severe than for mild cases both regarding mental health services ($697 vs. $388, χ2=4.4, P=.019) and antidepressants ($256 vs. $88, χ2=9.0, P=.001). Prevalence rates of unemployment/disability increased significantly (χ2=11.7, P=.003) with MDD severity (15.7, 23.3, and 31.3% for mild, moderate, and severe cases). Severely and moderately depressed workers missed more work than nondepressed workers; the monthly salary‐equivalent lost performance of $199 (severely depressed) and $188 (moderately depressed) was significantly higher than for nondepressed workers (χ2=10.3, P<.001). Projected to the US workforce, monthly depression‐related worker productivity losses had human capital costs of nearly $2 billion. Conclusions: MDD severity is significantly associated with increased treatment usage/costs, treatment adequacy, unemployment, and disability and with reduced work performance. Depression and Anxiety, 2010. © 2009 Wiley‐Liss, Inc.

[1]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[2]  D. Blazer,et al.  The economic burden of depression. , 1986, General hospital psychiatry.

[3]  E. Berndt,et al.  The economic burden of depression in 1990. , 1993, The Journal of clinical psychiatry.

[4]  A. Rush,et al.  The Inventory of Depressive Symptomatology (IDS): psychometric properties , 1996, Psychological Medicine.

[5]  A. Rush,et al.  The inventory of depressive symptomatology (IDS) , 1996 .

[6]  Thomas J. Carmody,et al.  The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‐C) and Self‐Report (IDS‐SR) ratings of depressive symptoms , 2000 .

[7]  H. Birnbaum,et al.  Identification of claims data “signature” and economic consequences of treatment-resistant depression , 2001, European Neuropsychopharmacology.

[8]  J. Zeber,et al.  The cost-utility of screening for depression in primary care. , 2001, Annals of internal medicine.

[9]  A. Rush,et al.  The impact of treatment-resistant depression on health care utilization and costs. , 2002, The Journal of clinical psychiatry.

[10]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[11]  Ronald C. Kessler,et al.  The World Health Organization Health and Work Performance Questionnaire (HPQ) , 2003, Journal of occupational and environmental medicine.

[12]  David Morganstein,et al.  Cost of lost productive work time among US workers with depression. , 2003, JAMA.

[13]  J. Markowitz,et al.  The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.

[14]  Ronald C Kessler,et al.  The economic burden of depression in the United States: how did it change between 1990 and 2000? , 2003, The Journal of clinical psychiatry.

[15]  Olga V. Demler,et al.  The US National Comorbidity Survey Replication (NCS‐R): design and field procedures , 2004, International journal of methods in psychiatric research.

[16]  A. Rush,et al.  The cost consequences of treatment-resistant depression. , 2004, The Journal of clinical psychiatry.

[17]  B. Bloom Prevalence and economic effects of depression. , 2004, Managed care.

[18]  Paul E. Stang,et al.  Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to Evaluate the Indirect Workplace Costs of Illness , 2004, Journal of occupational and environmental medicine.

[19]  B. Grant,et al.  Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. , 2005, Archives of general psychiatry.

[20]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[21]  R. Kessler,et al.  Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. , 2006, The American journal of psychiatry.

[22]  M. Alegría,et al.  Psychiatric Disorders and Labor Market Outcomes: Evidence from the National Latino and Asian American Study , 2005, Health economics.

[23]  B. Grant,et al.  The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions , 2007, Psychological Medicine.

[24]  R. Kessler,et al.  Comparative and Interactive Effects of Depression Relative to Other Health Problems on Work Performance in the Workforce of a Large Employer , 2008, Journal of occupational and environmental medicine.

[25]  P. Greenberg,et al.  Economic Implications of Treatment-Resistant Depression Among Employees , 2012, PharmacoEconomics.